- pregnant and/or planned to be pregnant within in next 6 months - age 49 or younger at time of enrollment - prior inpatient hospitalization for covid-19 (prior emergency department [ed] visits are not an exclusion criteria) - prior enrollment on a separate covid-19-related therapeutric trial (subsequent co-enrollment is permitted for patinets randomized to the control arm). - notably, concurrent use of covid-directed therapies is no longer an exclusion criteria for this trial. this includes azithromycin, dexamethasone, remdesevir, convalescent plasma, or any other coviddirected drug therapy.

- pregnant and/or planned to be pregnant within in next 6 months - age 49 or younger at time of enrollment - prior inpatient hospitalization for covid-19 (prior emergency department [ed] visits are not an exclusion criteria) - prior enrollment on a separate covid-19-related therapeutric trial (subsequent co-enrollment is permitted for patinets randomized to the control arm). - notably, concurrent use of covid-directed therapies is no longer an exclusion criteria for this trial. this includes azithromycin, dexamethasone, remdesevir, convalescent plasma, or any other coviddirected drug therapy.

- no use of disallowed medications prior to randomization: remdesivir or whatever drug may have been approved as standard of care to treat covid patients. after consenting and randomization, patient could get remdesivir and/or other approved standard of care treatments on the standard of care arm as physician's choice. however, they would not be allowed to receive this on the radiotherapy arm until interim analysis is completed (i.e., after the first 8 patients enrolled on both arms with at least 14 day follow-up. this would especially be the case, if we see a vast superiority of one arm over another for the primary endpoints, that puts patients at risks from obtaining the standard of care treatments) however, patient could recieve such therapy if they are mechanically ventilated. - pregnant and/or planned to be pregnant within in next 6 months

- no use of disallowed medications prior to randomization: remdesivir or whatever drug may have been approved as standard of care to treat covid patients. after consenting and randomization, patient could get remdesivir and/or other approved standard of care treatments on the standard of care arm as physician's choice. however, they would not be allowed to receive this on the radiotherapy arm until interim analysis is completed (i.e., after the first 8 patients enrolled on both arms with at least 14 day follow-up. this would especially be the case, if we see a vast superiority of one arm over another for the primary endpoints, that puts patients at risks from obtaining the standard of care treatments) however, patient could recieve such therapy if they are mechanically ventilated. - pregnant and/or planned to be pregnant within in next 6 months